Recenlty SQNM reported an 11% drop in Q4 revenue based on weak sales in its MassArray equipment and associated products.
SQNM is preparing to launch the next generation MassArray and the medical community is probably waiting on this upgrade to purchase which would have been a prime driver for the decline.
A recent upgrade sent SQNM higher and has pulled back off of the high.
SQNM had plummeted after issues in the past on its Down-Syndrome test however they continue to focus its resources on a DNA versions of its molecular diagnostics test for Down's syndrome.
6 and 7 Calls in the near to outer months are showing decent premiums. Currently May 6 at 1.20 with an underlying price of 6.63 and May 7 at .69.
Happy Trading...
No comments:
Post a Comment